PPARδ activity in cardiovascular diseases: A potential pharmacological target.
Activation of peroxisome proliferator-activated receptors (PPARs), and particularly of PPARα and PPARγ, using selective agonists, is currently used in the treatment of metabolic diseases such as hypertriglyceridemia and type 2 diabetes mellitus. PPARα and PPARγ anti-inflammatory, antiproliferative and antiangiogenic properties in cardiovascular cells were extensively clarified in a variety of in vitro and in vivo models. In contrast, the role of PPARδ in cardiovascular system is poorly understood. Prostacyclin, the predominant prostanoid released by vascular cells, is a putative endogenous agonist for PPARδ, but only recently PPARδ selective synthetic agonists were found, improving studies about the physiological and pathophysiological roles of PPARδ activation. Recent reports suggest that the PPARδ activation may play a pivotal role to regulate inflammation, apoptosis, and cell proliferation, suggesting that this transcriptional factor could become an interesting pharmacological target to regulate cardiovascular cell apoptosis, proliferation, inflammation, and metabolism.
Tesse
Angela
A
Laboratoire de Biologie Neurovasculaire Intégrée (LBNVI), UMR CNRS 6214/INSERM 771, Faculté de Médecine, Université d'Angers, rue Haute de Reculée, 49045 Angers Cedex 01, France. angela.tesse@univ-angers.fr
Andriantsitohaina
Ramaroson
R
Ragot
Thierry
T